Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2007 1
2008 1
2009 2
2010 1
2011 1
2012 1
2014 3
2015 2
2017 2
2018 3
2019 3
2020 1
2021 7
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.
Fenton SE, Zannikou M, Ilut L, Fischietti M, Ji C, Oku CV, Horvath CM, Le Poole IC, Bosenberg M, Bartom ET, Kocherginsky M, Platanias LC, Saleiro D. Fenton SE, et al. Mol Cancer Res. 2023 Apr 1;21(4):332-344. doi: 10.1158/1541-7786.MCR-22-0684. Mol Cancer Res. 2023. PMID: 36573964 Free PMC article.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
Hussain M, Carducci MA, Clarke N, Fenton SE, Fizazi K, Gillessen S, Jacene H, Morris MJ, Saad F, Sartor O, Taplin ME, Vapiwala N, Williams S, Sweeney C. Hussain M, et al. Among authors: fenton se. J Clin Oncol. 2022 Sep 10;40(26):3011-3014. doi: 10.1200/JCO.22.00208. Epub 2022 Apr 19. J Clin Oncol. 2022. PMID: 35439030 No abstract available.
PARP Inhibition in Advanced Prostate Cancer.
Fenton SE, Chalmers ZR, Hussain M. Fenton SE, et al. Cancer J. 2021 Nov-Dec 01;27(6):457-464. doi: 10.1097/PPO.0000000000000560. Cancer J. 2021. PMID: 34904808 Review.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
34 results